Guidance Archives - Page 87 of 637

2 minute read

Walgreens Boots Alliance Cuts Higher End Of 2024 Profit Outlook, Takes $5.8B Impairment Charge Related To VillageMD Business

March 28, 8:54 AM

Walgreens Boots Alliance's Q2 FY24 performance: Sales rise 6.3% to $37.1 billion, beating estimates. Adjusted EPS up 3.4% at $1.20. Notable growth in Pharmacy segment, despite retail challenges. Revised FY24 EPS guidance: $3.20-$3.35.

WBA

2 minute read

Why Chemical Company Chemours Shares Are Plunging Premarket Today

By Lekha Gupta

March 28, 8:16 AM

Chemours shares fall as internal review reveals delayed payments and lack of transparency in management.

1 minute read

BYD’s Electric Dream: Reportedly Doubling Down On International Sales To Outpace Tesla And Dominate Global EV Race

By Shivani Kumaresan

March 27, 12:36 PM

Chinese electric vehicle maker BYD Company has reportedly outlined ambitious sales targets for 2024, aiming to reach 3.6 million units, marking a 20% increase from its previous sales.

BYDDF

1 minute read

Why Clothing Company Lands’ End Shares Are Jumping Today

By Nabaparna Bhattacharya

March 27, 12:10 PM

Lands' End shares surge as fourth-quarter earnings beat expectations, driven by strong gross profit margins and optimistic outlook despite revenue decline.

1 minute read

Why Corporate Apparel Company Cintas Shares Are Gaining Today

By Nabaparna Bhattacharya

March 27, 11:58 AM

Cintas Corporation shares surge as third-quarter earnings beat expectations, with robust revenue growth and raised annual outlook.

CTAS

2 minute read

Cruiseline Operator Carnival Stock Slides – Here’s Why

By Shivani Kumaresan

March 27, 10:51 AM

Carnival reported first-quarter FY24 sales growth of 22% year-on-year to $5.406 billion, slightly missing the analyst consensus estimate. Total customer deposits reached a first-quarter record of $7.0 billion, surpassing the previous first-quarter record by $1.3 billion.

CCL

2 minute read

Podcast: LSD ‘Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics’ Says MindMed’s R. Barrow

By Lara Goldstein

March 27, 10:25 AM

Welcome to a new episode of the Benzinga Psychedelics Podcast where we’re joined by Robert Barrow, CEO of…

MNMD

1 minute read

Carnival Sees Q2 EPS ~$(0.03) Vs $(0.03) Est.; FY23 EPS ~$0.98 Vs $0.99 Est.

By Benzinga Newsdesk

March 27, 9:42 AM

2024 2Q 3Q 4Q FullYearALBDs (in millions) (a) 23.5 25.2 23.7 95.4 (a) See "Notes to Statistical Information" 2Q 2024 Full Year

CCL

2 minute read

Why Is Obesity Drug Developer Altimmune Stock Trading Lower On Wednesday?

By Vandana Singh

March 27, 9:31 AM

Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipose tissue, and results in obesity and Metabolic dysfunction-associated steatohepatitis trials.

ALT

2 minute read

Concentrix Sees Q2 EPS $2.55-$2.70 Vs $2.83 Est.; Revenue $2.325B-$2.372B Vs $2.37B Est.; FY24 EPS $11.69-$12.50 Vs $11.96 Est.; Revenue $9.51B-$9.70B Vs $9.63B Est

By Benzinga Newsdesk

March 26, 4:11 PM

Second Quarter Fiscal 2024 Expectations:Second quarter reported revenue is expected to be in the range of $2.325 billion to $2.372 billion. Based on current exchange rates, our expectations assume an approximately

CNXC